The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | Is it prime-time for CAR-T in myeloma?
Nina Shah
• 7 Dec 2019
Nina Shah, MD, University of California-San Francisco, San Francisco, CA, gives an overview of the CAR T-cell therapy landscape in multiple myeloma (MM) and what we can expect to see in the future. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
